Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective

Abstract

Diabetes mellitus is a disease that affects millions of people worldwide and its prevalence is estimated to rise in the future. Billions of dollars are spent each year around the world in health expenditure related to diabetes. There are several anti-diabetic drugs in the market for the treatment of non-insulin dependent diabetes mellitus. In this article, we will be talking about a relatively new class of anti-diabetic drugs called sodium glucose co-transporter 2 (SGLT2) inhibitors. This class of drugs has a unique mechanism of action focusing on inhibition of glucose reabsorption that separates it from other classes. This article covers the mechanism of glucose reabsorption in the kidneys, the mechanism of action of SGLT2 inhibitors, several SGLT2 inhibitors currently available in the market as well as those in various phases of development, their individual pharmacokinetics as well as the discussion about the future role of SGLT2 inhibitors, not only for the treatment of diabetes, but also for various other diseases like obesity, hepatic steatosis, and cardiovascular disorders.

Keywords: Canagliflozin (Pubchem CID: 24812758); Cardiovascular; Clinical; Dapagliflozin (Pubchem CID: 9887712); Empagliflozin (Pubchem CID: 11949646); Ipragliflozin (Pubchem CID: 10453870); Luseogliflozin (Pubchem CID: 11988953); Obesity; Pharmacokinetics; Remogliflozin etabonate (Pubchem CID: 9871420); SGLT2 inhibitors; Sodium glucose cotransporter; Tofogliflozin (Pubchem CID: 46908929).